In heart failure, all beta-blockers are not necessarily equal

W. H.Wilson Tang, Michael Militello, Gary S. Francis

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate. Whether the target doses used were equivalent (carvedilol 25 mg twice daily vs metoprolol tartrate 50 mg twice daily) has been debated, but the COMET trial shows that drugs in the same class do not necessarily have the same effects. Given the overwhelming evidence of the benefit of carvedilol, metoprolol succinate, and bisoprolol in patients with heart failure, we should all strive to increase the use of these drugs in appropriate doses.

Original languageEnglish (US)
Pages (from-to)1081-1087
Number of pages7
JournalCleveland Clinic journal of medicine
Volume70
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint Dive into the research topics of 'In heart failure, all beta-blockers are not necessarily equal'. Together they form a unique fingerprint.

Cite this